● Recruiting

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Condition: Locally Advanced Pancreatic Adenocarcinoma · Locally Advanced Pancreas Cancer · Locally Advanced Pancreatic Ductal Adenocarcinoma · Sponsor: Xerient Pharma

PhasePhase 1/Phase 2

Planned participants36

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.

This description comes directly from the study's public registry record.

Talk to the study team

Robbin Frnka · 2142055746 · rfrnka@accelsobio.com

Jeanne Jones · jjones@accelsobio.com

Always discuss trial participation with your own doctor first.

Locations (4)

City of Hope	Duarte, California, United States	Recruiting
CIty of Hope	Irvine, California, United States	Recruiting
Christus St. Vincent Regional Cancer Center	Santa Fe, New Mexico, United States	Recruiting
Oncology Consultants, P.A.	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07157033